Sermorelin Acetate 10mg

For research use only — not for human or veterinary use.

Analytical Verification (COA)

Each batch of Sermorelin Acetate supplied by Grail Formula undergoes independent third-party laboratory verification to confirm compound identity, assay content, purity and microbiological safety.

Analytical testing for this batch was performed by Liquilabs s.r.o. (Czechia) using validated chromatographic and spectrometric techniques.

Batch: GF122025095

Key analytical results include:

• Assay Content: 10.52 mg
• Identification – Retention Time: 0.997
• Identification – Spectrum: 996
• Purity: approximately 99.3 percent
• Bacterial Endotoxins: below 0.001 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected

Independent heavy metal screening confirmed no detectable levels of arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium.

These analytical procedures ensure traceability, purity verification and laboratory-grade compound consistency.

Product Overview

Sermorelin Acetate is a synthetic peptide research compound frequently studied in controlled laboratory environments investigating growth hormone releasing hormone (GHRH) signalling pathways and endocrine regulatory mechanisms.

The compound is a synthetic analogue derived from fragments of endogenous growth hormone releasing hormone and is commonly examined in experimental models exploring peptide-mediated endocrine signalling.

This preparation contains 10 mg of high purity lyophilized peptide supplied in a sealed research vial. The lyophilization process preserves peptide stability and allows researchers to reconstitute the compound for controlled in vitro experimentation.

Because of its defined peptide structure and stable analytical profile, Sermorelin Acetate has become a widely referenced compound in experimental peptide and endocrine signalling research models.

Compound Overview

Sermorelin Acetate is a synthetic peptide analogue corresponding to the first 29 amino acids of endogenous growth hormone releasing hormone (GHRH).

Growth hormone releasing hormone plays an important role in endocrine signalling systems that regulate growth hormone secretion pathways.

Research involving Sermorelin Acetate frequently explores its interaction with GHRH receptors and associated intracellular signalling cascades.

Due to its defined peptide structure and receptor interaction profile, Sermorelin Acetate is widely used in controlled laboratory environments investigating endocrine regulatory mechanisms and peptide-mediated signalling pathways.

Historical Background and Scientific Context

Scientific interest in growth hormone regulatory pathways expanded significantly during the late twentieth century as advances in molecular biology allowed researchers to map endocrine signalling networks.

During this period growth hormone releasing hormone was identified as a key regulatory peptide controlling pituitary growth hormone secretion.

Researchers subsequently developed synthetic analogues derived from fragments of endogenous GHRH to investigate receptor signalling and endocrine regulation in controlled laboratory models.

Sermorelin Acetate emerged as one of these synthetic peptide analogues used in experimental research examining endocrine signalling systems.

Mechanistic Focus in Research

Within experimental laboratory settings, Sermorelin Acetate is commonly studied in relation to endocrine signalling and peptide-mediated regulatory pathways.

Research investigations commonly explore the compound in experimental models examining:

• Growth hormone releasing hormone receptor signalling
• Endocrine regulatory pathway analysis
• Peptide receptor interaction mechanisms
• Intracellular signalling cascade modelling
• Comparative peptide signalling research
• Hormonal regulatory network studies
• Peptide-mediated endocrine communication

These experimental models allow scientists to investigate molecular signalling mechanisms that regulate endocrine communication and cellular regulatory processes.

Research Applications

In controlled research environments, Sermorelin Acetate may be utilised in experimental models designed to explore endocrine signalling and peptide regulatory systems.

Examples of research applications include:

• Growth hormone signalling studies
• Endocrine pathway investigation
• Peptide receptor interaction analysis
• Molecular hormonal signalling research
• Comparative peptide compound evaluation
• Intracellular endocrine network modelling
• Controlled in vitro peptide studies

Grail Formula Quality

Every Grail Formula research compound is produced under strict quality control procedures designed to support reliable laboratory experimentation.

Each batch undergoes independent analytical testing to verify:

• Compound identity
• Assay accuracy
• Purity confirmation
• Microbial safety
• Endotoxin levels
• Heavy metal screening
• Full batch traceability

All testing is performed by independent laboratories to ensure transparent verification and reproducible research material.

Research Use Limitation

• Used solely for in vitro experiments
• Not permitted for clinical trials involving humans
• Not permitted for human or veterinary administration
• Not permitted for investigational human use

Verified and analysed with Liquilabs s.r.o. (Czechia)
High-purity Sermorelin Acetate research peptide
Validated assay content 10.52 mg with purity 99.3 percent
Retention time and spectral identification confirmed
Endotoxin levels below 0.001 EU per mg
No detectable microbial growth or heavy metals
For research use only — not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.